Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

November 30, 2022

Study Completion Date

November 1, 2023

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Fasudil

Fasudil hydrochloride hydrate IV solution

DRUG

Placebo

Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%

Trial Locations (15)

37075

University Medical Center Göttingen, Göttingen

Unknown

Centre Hospitalier Universitaire Marseille, Marseille

Centre Hospitalier Universitaire Montpellier, Montpellier

Centre Hospitalier Universitaire Nice, Nice

Centre Hospitalier Universitaire Tours, Tours

Charité Universitätsmedizin Berlin, Berlin

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

Universitätsklinikum Halle (Saale), Halle

Medizinische Hochschule Hannover, Hanover

Universitätsklinikum Jena, Jena

Universitätsklinikum Leipzig, Leipzig

Klinikum rechts der Isar der Technischen Universität München, München

Universitätsklinikum Ulm, Ulm

University of Würzburg, Würzburg

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors
lead

University Medical Center Goettingen

OTHER

NCT03792490 - Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS | Biotech Hunter | Biotech Hunter